Radiation therapy for the treatment of locally advanced and metastatic prostate cancer

S. A. Thurman, N. R. Ramakrishna, Theodore DeWeese

Research output: Contribution to journalArticle

Abstract

Radiation therapy for locally advanced PCa continues to evolve. A current treatment recommendation for nonmetastatic, high-risk disease includes AS combined with RT. The precise duration and sequencing of AS has not been established but most frequently includes treatment in the neoadjuvant, concomitant and, occasionally, adjuvant periods. As technology allows higher doses without significant increases in morbidity and as clinical data provide proof of a radiation dose response, RT doses continue to escalate. The goal of therapy for metastatic disease continues to focus on the relief of pain and the improvement in quality of life. Multiple studies document the significant role RT plays in achieving these goals. Focal RT and systemic radioisotopes have become the mainstay of management in this patient group and the development of newer isotopes that cause less marrow toxicity will improve the therapeutic ratio and provide an opportunity for their use with systemic chemotherapy. As molecular and genomic technologies advance, directed targeting of critical cellular radiation-response pathways hold the promise of improved radiation response and individualized, tailored therapy.

Original languageEnglish (US)
Pages (from-to)423-443
Number of pages21
JournalHematology/Oncology Clinics of North America
Volume15
Issue number3
DOIs
StatePublished - 2001

Fingerprint

Prostatic Neoplasms
Radiotherapy
Radiation
Technology
Neoadjuvant Therapy
Therapeutics
Radioisotopes
Isotopes
Bone Marrow
Quality of Life
Morbidity
Drug Therapy
Pain

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Radiation therapy for the treatment of locally advanced and metastatic prostate cancer. / Thurman, S. A.; Ramakrishna, N. R.; DeWeese, Theodore.

In: Hematology/Oncology Clinics of North America, Vol. 15, No. 3, 2001, p. 423-443.

Research output: Contribution to journalArticle

@article{2b47ab5325094c58ab56f00e2f4d179d,
title = "Radiation therapy for the treatment of locally advanced and metastatic prostate cancer",
abstract = "Radiation therapy for locally advanced PCa continues to evolve. A current treatment recommendation for nonmetastatic, high-risk disease includes AS combined with RT. The precise duration and sequencing of AS has not been established but most frequently includes treatment in the neoadjuvant, concomitant and, occasionally, adjuvant periods. As technology allows higher doses without significant increases in morbidity and as clinical data provide proof of a radiation dose response, RT doses continue to escalate. The goal of therapy for metastatic disease continues to focus on the relief of pain and the improvement in quality of life. Multiple studies document the significant role RT plays in achieving these goals. Focal RT and systemic radioisotopes have become the mainstay of management in this patient group and the development of newer isotopes that cause less marrow toxicity will improve the therapeutic ratio and provide an opportunity for their use with systemic chemotherapy. As molecular and genomic technologies advance, directed targeting of critical cellular radiation-response pathways hold the promise of improved radiation response and individualized, tailored therapy.",
author = "Thurman, {S. A.} and Ramakrishna, {N. R.} and Theodore DeWeese",
year = "2001",
doi = "10.1016/S0889-8588(05)70224-0",
language = "English (US)",
volume = "15",
pages = "423--443",
journal = "Hematology/Oncology Clinics of North America",
issn = "0889-8588",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Radiation therapy for the treatment of locally advanced and metastatic prostate cancer

AU - Thurman, S. A.

AU - Ramakrishna, N. R.

AU - DeWeese, Theodore

PY - 2001

Y1 - 2001

N2 - Radiation therapy for locally advanced PCa continues to evolve. A current treatment recommendation for nonmetastatic, high-risk disease includes AS combined with RT. The precise duration and sequencing of AS has not been established but most frequently includes treatment in the neoadjuvant, concomitant and, occasionally, adjuvant periods. As technology allows higher doses without significant increases in morbidity and as clinical data provide proof of a radiation dose response, RT doses continue to escalate. The goal of therapy for metastatic disease continues to focus on the relief of pain and the improvement in quality of life. Multiple studies document the significant role RT plays in achieving these goals. Focal RT and systemic radioisotopes have become the mainstay of management in this patient group and the development of newer isotopes that cause less marrow toxicity will improve the therapeutic ratio and provide an opportunity for their use with systemic chemotherapy. As molecular and genomic technologies advance, directed targeting of critical cellular radiation-response pathways hold the promise of improved radiation response and individualized, tailored therapy.

AB - Radiation therapy for locally advanced PCa continues to evolve. A current treatment recommendation for nonmetastatic, high-risk disease includes AS combined with RT. The precise duration and sequencing of AS has not been established but most frequently includes treatment in the neoadjuvant, concomitant and, occasionally, adjuvant periods. As technology allows higher doses without significant increases in morbidity and as clinical data provide proof of a radiation dose response, RT doses continue to escalate. The goal of therapy for metastatic disease continues to focus on the relief of pain and the improvement in quality of life. Multiple studies document the significant role RT plays in achieving these goals. Focal RT and systemic radioisotopes have become the mainstay of management in this patient group and the development of newer isotopes that cause less marrow toxicity will improve the therapeutic ratio and provide an opportunity for their use with systemic chemotherapy. As molecular and genomic technologies advance, directed targeting of critical cellular radiation-response pathways hold the promise of improved radiation response and individualized, tailored therapy.

UR - http://www.scopus.com/inward/record.url?scp=0034882849&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034882849&partnerID=8YFLogxK

U2 - 10.1016/S0889-8588(05)70224-0

DO - 10.1016/S0889-8588(05)70224-0

M3 - Article

C2 - 11525289

AN - SCOPUS:0034882849

VL - 15

SP - 423

EP - 443

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

SN - 0889-8588

IS - 3

ER -